Note: The New England Journal of Medicine released an article outlining the results of a study of a new drug, Emicizumab (ACE910, Chugai Pharmaceuticals), that shows reduced bleeding in patients with severe hemophilia A. Read the full article, Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A, in the New England Journal of Medicine. This video from The New England Journal of Medicine explains how Emicizumab works.
The below is an excerpt that was published in HemOnc Today as follow-up summary article. The original release can be read in its entirety here.
Emicizumab Reduces Bleeding In Patients With Severe Hemophilia A
HemOnc Today
By Cameron Kelsall
May 25, 2016
“Weekly subcutaneous administration of the bispecific antibody emicizumab decreased the rate of bleeding events in patients with hemophilia A, according to the results of a dose-escalation study.
The responses remained robust in patients with or without factor VIII inhibitors, results showed.
Regular prophylactic and episodic IV infusions of factor VIII serve as the standard of care for patients with hemophilia A.”
The original release can be read in its entirety here.
